Literature DB >> 35059120

Novel Macrocyclic Peptidylarginine Deiminase Type 4 (PAD4) Inhibitors.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2022        PMID： 35059120      PMCID： PMC8762737          DOI： 10.1021/acsmedchemlett.1c00689

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  6 in total

Review 1.  Towards prevention of autoimmune diseases: The example of rheumatoid arthritis.

Authors:  Aase Hensvold; Lars Klareskog
Journal:  Eur J Immunol       Date:  2021-07-03       Impact factor: 5.532

Review 2.  Current knowledge into the role of the peptidylarginine deiminase (PAD) enzyme family in cardiovascular disease.

Authors:  Doa'a G F Al-U'datt; Bruce G Allen; Roddy Hiram; Nasr Alrabadi
Journal:  Eur J Pharmacol       Date:  2020-11-26       Impact factor: 4.432

Review 3.  Neutrophil Dysregulation in the Pathogenesis of Systemic Lupus Erythematosus.

Authors:  Yudong Liu; Mariana J Kaplan
Journal:  Rheum Dis Clin North Am       Date:  2021-06-09       Impact factor: 2.670

Review 4.  Epigenetic regulation of cellular functions in wound healing.

Authors:  Irena Pastar; Jelena Marjanovic; Rivka C Stone; Vivien Chen; Jamie L Burgess; Joshua S Mervis; Marjana Tomic-Canic
Journal:  Exp Dermatol       Date:  2021-04-01       Impact factor: 4.511

Review 5.  Is diabetes mellitus a wrongdoer to COVID-19 severity?

Authors:  Sanjib Sarkar; Dibyendu Das; Sawlang Borsingh Wann; Jatin Kalita; Prasenjit Manna
Journal:  Diabetes Res Clin Pract       Date:  2021-07-01       Impact factor: 5.602

Review 6.  Crosstalk between B cells and neutrophils in rheumatoid arthritis.

Authors:  Utsa Karmakar; Sonja Vermeren
Journal:  Immunology       Date:  2021-09-08       Impact factor: 7.397
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.